Press Release

Nextcea files patent infringement litigation against Lipotype.

US patent ribbon US Patent No. 8,313,949

Bloomberg Law

reports Nextcea Patent Suit Targets Lipotype Fat-Based Diagnostic Tests
Complaint Exhibit A Exhibit B Exhibit C

Applied biomarker services to neurodegenerative diseases

Biomarker and drug target engagement services including Parkinson’s, Gaucher disease, Dementia, Leukemia

Globally focused with pharmaceuticals across the world

Drug efficacy PK/PD and safety assessments via plasma, CSF, and urine for clinical and non-clinical studies

Nextcea performs Drug Efficacy & Safety Assessments
using proprietary biomarkers through advanced LC-MS/MS platforms

LRRK2

Parkinson’s disease

GBA

Parkinson’s disease & Gaucher disease

BTK

Leukemia / Lymphoma

Phospholipidosis

Drug-Induced Phospholipidosis / Parkinsonism

Nextcea is dedicated to optimizing efficacy and minimizing toxicity in all phases of drug development.

Kidney Safety Assessment

for Oligonucleotide drug candidates